Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
51
pubmed:dateCreated
2010-12-3
pubmed:abstractText
Polysaccharide-based vaccines against Neisseria meningitidis (Nm) serogroups A, C, Y and W135 have been available since 1970, but similar vaccine candidates developed for Nm group B (NmB) have not been successful due to both poor immunogenicity and their potential immunological cross-reactivity with human neurological tissue. In previous reports, a protective antigen and vaccine candidate, Ag473, was identified using proteomics and NmB-specific bactericidal monoclonal antibody. To initiate human phase one clinical trials, antigen production and characterization, pre-clinical toxicology and animal studies are required. In the present study, we report the biochemical characterization of Escherichia coli-expressed recombinant Ag473 (rAg473). Using MALDI-TOF mass analysis, chromatographically purified rAg473 was found to have two major isoforms that have molecular masses of 11,306 and 11,544amu, respectively. The isoforms were separated using RP-HPLC and pooled into two fractions. Based on the chromatogram, the ratio of lipoproteins in fractions #1 and #2 was found to be 1-2. GC-MS analysis of lipoproteins was performed, and the acylated fatty acids were identified. The results indicated that the first lipoproteins in fraction #1 contained the lipids palmitic acid (C16:0), cyclopropaneoctanoic acid (C17:1) and, predominately, stearic acid (C18:0). A different lipid composition of cyclopropaneoctanoic acid (C17:1), oleic acid (C18:1) and, predominately, palmitic acid (C16:0) was found in the second lipoprotein fraction. Both lipoprotein isoforms were tested and found to have Toll-like receptor (TLR) agonist activity in stimulating cytokine secretion from THP-1 cells. Circular dichroism (CD) analysis showed the secondary structure of rAg473 to be dominated by ?-helices (48%), and the overall protein structure was stable up to 60°C and could refold after having been exposed to a temperature cycle from 20 to 90°C. In addition, the solubility of rAg473 (5mg/mL) was not affected after several freeze-thaw cycles. These biophysical and immunological properties make rAg473 a good vaccine candidate against NmB.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1873-2518
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
29
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8175-82
pubmed:meshHeading
pubmed-meshheading:20937316-Animals, pubmed-meshheading:20937316-Antibodies, Bacterial, pubmed-meshheading:20937316-Antigens, Bacterial, pubmed-meshheading:20937316-Bacterial Proteins, pubmed-meshheading:20937316-Chromatography, pubmed-meshheading:20937316-Chromatography, High Pressure Liquid, pubmed-meshheading:20937316-Circular Dichroism, pubmed-meshheading:20937316-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:20937316-Escherichia coli, pubmed-meshheading:20937316-Fatty Acids, pubmed-meshheading:20937316-Gas Chromatography-Mass Spectrometry, pubmed-meshheading:20937316-Gene Expression, pubmed-meshheading:20937316-Hot Temperature, pubmed-meshheading:20937316-Immunoglobulin G, pubmed-meshheading:20937316-Lipoproteins, pubmed-meshheading:20937316-Mice, pubmed-meshheading:20937316-Mice, Inbred BALB C, pubmed-meshheading:20937316-Molecular Weight, pubmed-meshheading:20937316-Neisseria meningitidis, Serogroup B, pubmed-meshheading:20937316-Protein Conformation, pubmed-meshheading:20937316-Protein Isoforms, pubmed-meshheading:20937316-Protein Stability, pubmed-meshheading:20937316-Recombinant Proteins, pubmed-meshheading:20937316-Spectrometry, Mass, Matrix-Assisted Laser..., pubmed-meshheading:20937316-Toll-Like Receptors
pubmed:year
2010
pubmed:articleTitle
Biochemical characterizations of Escherichia coli-expressed protective antigen Ag473 of Neisseria meningitides group B.
pubmed:affiliation
Vaccine Research and Development Center, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't